Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive.
作者信息
Ewers Michael, Ioannidis John P A, Plesnila Nikolaus
机构信息
Institute for Stroke and Dementia Research, University Hospital Munich, Ludwig Maximilian University, Munich, Germany; LMU Open Science Center (OSC), Ludwig Maximilian University, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich.
Department of Medicine, Department of Epidemiology and Population Health, Department of Biomedical Data Science, Department of Statistics, Meta-Research Innovation Center at Stanford (METRICS), Stanford University, CA, USA.
出版信息
J Clin Epidemiol. 2021 Feb;130:143-146. doi: 10.1016/j.jclinepi.2020.10.008. Epub 2020 Oct 14.
Abstract
摘要
相似文献
1
Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive.
J Clin Epidemiol. 2021 Feb;130:143-146. doi: 10.1016/j.jclinepi.2020.10.008. Epub 2020 Oct 14.
2
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
3
Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.
Int J Antimicrob Agents. 2021 Jan;57(1):106254. doi: 10.1016/j.ijantimicag.2020.106254. Epub 2020 Nov 28.
4
COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.
Pharmacotherapy. 2020 May;40(5):379-381. doi: 10.1002/phar.2396. Epub 2020 May 5.
5
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
6
Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Biomedica. 2020 Oct 30;40(Supl. 2):80-95. doi: 10.7705/biomedica.5478.
7
Searching for COVID-19 treatments: First, do no harm.
Am J Health Syst Pharm. 2020 Oct 30;77(22):1899-1905. doi: 10.1093/ajhp/zxaa257.
8
How COVID broke the evidence pipeline.
Nature. 2021 May;593(7858):182-185. doi: 10.1038/d41586-021-01246-x.
9
Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19.
JAMA Intern Med. 2021 Nov 1;181(11):1535-1537. doi: 10.1001/jamainternmed.2021.4112.
10
Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.
Pharmacotherapy. 2020 Nov;40(11):1072-1081. doi: 10.1002/phar.2467.
引用本文的文献
1
Evaluating the discoverability of supporting research materials in ClinicalTrials.gov for US federally funded COVID-19 clinical studies.
J Med Libr Assoc. 2024 Jul 1;112(3):250-260. doi: 10.5195/jmla.2024.1799. Epub 2024 Jul 29.
2
Transparency of COVID-19-related research: A meta-research study.
PLoS One. 2023 Jul 26;18(7):e0288406. doi: 10.1371/journal.pone.0288406. eCollection 2023.
3
Institutionalizing Open Science in Africa: Limitations and Prospects.
Front Res Metr Anal. 2022 Apr 15;7:855198. doi: 10.3389/frma.2022.855198. eCollection 2022.
4
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.
BMC Infect Dis. 2021 Nov 20;21(1):1170. doi: 10.1186/s12879-021-06829-7.
5
Challenges of evidence synthesis during the 2020 COVID pandemic: a scoping review.
J Clin Epidemiol. 2022 Feb;142:10-18. doi: 10.1016/j.jclinepi.2021.10.017. Epub 2021 Oct 27.
6
The Evolution of Clinical Knowledge During COVID-19: Towards a Global Learning Health System.
Yearb Med Inform. 2021 Aug;30(1):176-184. doi: 10.1055/s-0041-1726503. Epub 2021 Sep 3.
7
Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?
Can J Cardiol. 2021 Sep;37(9):1353-1364. doi: 10.1016/j.cjca.2021.05.009. Epub 2021 May 30.
8
Rapid response to emerging biomedical challenges and threats.
IUCrJ. 2021 Mar 26;8(Pt 3):395-407. doi: 10.1107/S2052252521003018. eCollection 2021 May 1.
9
New placebo-controlled Covid-19 vaccine trials are ethically questionable; it's now about comparative effectiveness and availability of registered vaccines.
J Clin Epidemiol. 2021 May;133:175-176. doi: 10.1016/j.jclinepi.2021.03.006. Epub 2021 Mar 16.
10
Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement.
JAMA Netw Open. 2021 Jan 4;4(1):e2033972. doi: 10.1001/jamanetworkopen.2020.33972.
本文引用的文献
1
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Nat Commun. 2021 Apr 15;12(1):2349. doi: 10.1038/s41467-021-22446-z.
2
Learning from a retraction.
Lancet. 2020 Oct 10;396(10257):1056. doi: 10.1016/S0140-6736(20)31958-9. Epub 2020 Sep 17.
3
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
4
Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters.
Environ Res. 2020 Sep;188:109890. doi: 10.1016/j.envres.2020.109890. Epub 2020 Jul 1.
5
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
6
Achieving effective informed oversight by DMCs in COVID clinical trials.
J Clin Epidemiol. 2020 Oct;126:167-171. doi: 10.1016/j.jclinepi.2020.07.001. Epub 2020 Jul 10.
7
Open synthesis and the coronavirus pandemic in 2020.
J Clin Epidemiol. 2020 Oct;126:184-191. doi: 10.1016/j.jclinepi.2020.06.032. Epub 2020 Jul 1.
8
A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.
J Clin Epidemiol. 2020 Sep;125:170-178. doi: 10.1016/j.jclinepi.2020.06.005. Epub 2020 Jun 8.
9
Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.
Lancet. 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6. Epub 2020 Jun 5.
10
Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.
Lancet. 2020 Jun 13;395(10240):e102. doi: 10.1016/S0140-6736(20)31290-3. Epub 2020 Jun 3.
Zotero 插件